Top

Published in:

01-01-2015 | Topic Review

Atypical meningoma: current management dilemmas and prospective clinical trials

Authors: Michael D. Jenkinson, Damien C. Weber, Brian J. Haylock, Conor L. Mallucci, Rasheed Zakaria, Mohsen Javadpour

Published in: Journal of Neuro-Oncology | Issue 1/2015

Abstract

Atypical meningioma is an intermediate grade tumour with a greater risk of recurrence following surgical resection. Changes to the WHO classification have resulted in an increased reporting of these tumours. The role of early adjuvant radiotherapy after gross total resection has not been clearly defined and the literature evidence is of poor quality providing conflicting information. This review assesses the evidence for current clinical practice, management dilemmas and the need for prospective clinical trials for atypical meningioma.

Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neuro-oncol 99(3):307–314. doi:10.1007/s11060-010-0386-3 CrossRef

Louis DN, Ohgaki H, Wiestler OD et al (2007) WHO classification of tumours of the central nervous system. IARC Press, Lyon

Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, Curry WT Jr, Barker FG II (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64(1):56–60. doi:10.1227/01.NEU.0000330399.55586.63 (discussion 60)PubMedCrossRef

Jo K, Park HJ, Nam DH, Lee JI, Kong DS, Park K, Kim JH (2010) Treatment of atypical meningioma. J.clin neurosci: off j Neurosurg Soc Australas 17(11):1362–1366. doi:10.1016/j.jocn.2010.03.036 CrossRef

Park HJ, Kang HC, Kim IH, Park SH, Kim DG, Park CK, Paek SH, Jung HW (2013) The role of adjuvant radiotherapy in atypical meningioma. J Neurooncol 115(2):241–247. doi:10.1007/s11060-013-1219-y PubMedCrossRef

Rogers L, Gilbert M, Vogelbaum MA (2010) Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol 99(3):393–405. doi:10.1007/s11060-010-0343-1 PubMedCrossRef

Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, Debus J, Combs SE (2012) Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas–clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys 83(3):859–864. doi:10.1016/j.ijrobp.2011.08.010 PubMedCrossRef

Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon

Pearson BE, Markert JM, Fisher WS, Guthrie BL, Fiveash JB, Palmer CA, Riley K (2008) Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus 24(5):E3. doi:10.3171/FOC/2008/24/5/E3 PubMedCrossRef

10.

Backer-Grondahl T, Moen BH, Torp SH (2012) The histopathological spectrum of human meningiomas. Int j clin exp pathol 5(3):231–242PubMedCentralPubMed

11.

Willis J, Smith C, Ironside JW, Erridge S, Whittle IR, Everington D (2005) The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol 31(2):141–149. doi:10.1111/j.1365-2990.2004.00621.x PubMedCrossRef

12.

Perry A (2006) Meningiomas. Russell and Rubinstein’s pathology of tumors of the nervous system, 7th edn. Hodder Arnold, London

13.

Hakyemez B, Yildirim N, Gokalp G, Erdogan C, Parlak M (2006) The contribution of diffusion-weighted MR imaging to distinguishing typical from atypical meningiomas. Neuroradiology 48(8):513–520. doi:10.1007/s00234-006-0094-z PubMedCrossRef

14.

Cabada T, Caballero MC, Insausti I, Alvarez de Eulate N, Bacaicoa C, Zazpe I, Tunon T (2009) The role of diffusion-weighted imaging in the evaluation of meningiomas: radio-pathologic correlation. Radiologia 51(4):411–419. doi:10.1016/j.rx.2009.01.017 PubMedCrossRef

15.

Kane AJ, Sughrue ME, Rutkowski MJ, Shangari G, Fang S, McDermott MW, Berger MS, Parsa AT (2011) Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer 117(6):1272–1278. doi:10.1002/cncr.25591 PubMedCentralPubMedCrossRef

16.

Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20(1):22–39PubMedCentralPubMedCrossRef

17.

Sughrue ME, Kane AJ, Shangari G, Rutkowski MJ, McDermott MW, Berger MS, Parsa AT (2010) The relevance of Simpson grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg 113(5):1029–1035. doi:10.3171/2010.3.JNS091971 PubMedCrossRef

18.

Komotar RJ, Iorgulescu JB, Raper DM, Holland EC, Beal K, Bilsky MH, Brennan CW, Tabar V, Sherman JH, Yamada Y, Gutin PH (2012) The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg 117(4):679–686. doi:10.3171/2012.7.JNS112113 PubMedCrossRef

19.

Mair R, Morris K, Scott I, Carroll TA (2011) Radiotherapy for atypical meningiomas. J Neurosurg 115(4):811–819. doi:10.3171/2011.5.JNS11112 PubMedCrossRef

20.

Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP (2010) Opportunities for clinical research in meningioma. J Neuro-oncol 99(3):417–422. doi:10.1007/s11060-010-0375-6 CrossRef

21.

Pollock BE (2013) Defining the best management for patients with intracranial World Health Organization grade II meningiomas. World neurosurg. doi:10.1016/j.wneu.2013.08.051

22.

Austin H, Hill HA, Flanders WD, Greenberg RS (1994) Limitations in the application of case-control methodology. Epidemiol Rev 16(1):65–76PubMed

23.

Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ, Barani IJ, James CD, Parsa AT (2014) Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neurooncol 16(5):628–636. doi:10.1093/neuonc/nou025

24.

Marcus HJ, Price SJ, Wilby M, Santarius T, Kirollos RW (2008) Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg 22(4):520–528. doi:10.1080/02688690802308687 PubMedCrossRef

25.

Simon M, Bostrom J, Koch P, Schramm J (2006) Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification. J Neurol Neurosurg Psychiatry 77(6):767–773. doi:10.1136/jnnp.2005.077974 PubMedCentralPubMedCrossRef

26.

Weber DC, Lovblad KO, Rogers L (2010) New pathology classification, imagery techniques and prospective trials for meningiomas: the future looks bright. Curr Opin Neurol 23(6):563–570. doi:10.1097/WCO.0b013e328340441e PubMedCrossRef

27.

Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC (1999) “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85(9):2046–2056PubMed

28.

Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F (2002) Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: protect (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ 325(7367):766–770PubMedCentralPubMedCrossRef

29.

Mills N, Donovan JL, Wade J, Hamdy FC, Neal DE, Lane JA (2011) Exploring treatment preferences facilitated recruitment to randomized controlled trials. J Clin Epidemiol 64(10):1127–1136. doi:10.1016/j.jclinepi.2010.12.017 PubMedCentralPubMedCrossRef

30.

O’Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Hewison J (2013) What can qualitative research do for randomised controlled trials? A systematic mapping review. BMJ open. doi:10.1136/bmjopen-2013-002889

31.

Preusser M, Spiegl-Kreinecker S, Lotsch D, Wohrer A, Schmook M, Dieckmann K, Saringer W, Marosi C, Berger W (2012) Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer 118(20):5038–5049. doi:10.1002/cncr.27460 PubMedCrossRef

32.

Vranic A, Peyre M, Kalamarides M (2012) New insights into meningioma: from genetics to trials. Curr Opin Oncol 24(6):660–665. doi:10.1097/CCO.0b013e3283571a06 PubMedCrossRef

33.

Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45(3):285–289. doi:10.1038/ng.2526 PubMedCentralPubMedCrossRef

34.

Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakcalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilguvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kilic T, Lifton RP, Noonan JP, Yasuno K, Gunel M (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123):1077–1080. doi:10.1126/science.1233009 PubMedCrossRef

Title: Atypical meningoma: current management dilemmas and prospective clinical trials
Authors: Michael D. Jenkinson
Damien C. Weber
Brian J. Haylock
Conor L. Mallucci
Rasheed Zakaria
Mohsen Javadpour
Publication date: 01-01-2015
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1620-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Atypical meningoma: current management dilemmas and prospective clinical trials

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Pediatric choroid plexus tumors: epidemiology, treatments, and outcome analysis on 202 children from the SEER database

Familial gliomas: cases in two pairs of brothers

Quantitative analysis of tumor volume reduction after three-dimensional conformal radiation therapy for intracranial meningiomas

Diabetes insipidus in pediatric germinomas of the suprasellar region: characteristic features and significance of the pituitary bright spot

Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging

Ipilimumab and whole brain radiation therapy for melanoma brain metastases